Integra LifeSciences Holdings Corporation

IART Healthcare Medical Devices

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.21 0.32 −2.37%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
26.1×
Dividend yield
—
F-score
5/9
Altman Z
0.62
Beneish M
−3.25
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.84 0.44 0.58 0.67
P/FCF ratio
53.80 177.67 0.00 0.00
P/Operating CF
60.88 73.94 80.59 26.89
P/B ratio
1.33 0.70 0.91 1.06
EV/Sales
1.84 1.44 1.53 1.95
EV/EBITDA
13.56 0.00 0.00 0.00
EV/FCF
117.46 581.82 (80.70) (708.68)
Current Ratio
3.60 3.38 2.54 3.14
Net Debt/EBITDA
26.60 30.67 24.86 29.55
Debt/Equity
1.75 1.75 1.74 1.73
Earnings Yield
(0.50%) (68.58%) (54.19%) (45.08%)
Free Cash Flow Yield
1.86% 0.56% (3.26%) (0.41%)
Free Cash Flow per Share
0.14 (0.07) (0.07) 0.34
Book value per Share
13.50 13.55 13.61 13.52
Free Cash Flow
10.50 (5.04) (5.40) 25.75
EV/EBIT
46.23 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates